Catalog No.
KDA29102
Stability and Storage
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection method
Colorimetric
Precision
CV<20%
Sample type
Plasma, Serum
Assay type
Quantitative
Sensitivity
0.156 μg/ml
Range
0.31-5 μg/mL
Recovery
80-120%
Specifications
Conatumumab
Alternative Names
AMG 655, TRAIL-R2mAb, XG1-048 v w, CAS: 896731-82-1
Background
Conatumumab (previously called AMG-655) is a fully human Immunoglobulin G1 (IgG1) type monoclonal binding to tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) which could induce apoptosis in many types of human cancer cells. This drug was developed by Amgen Inc and Japanese licensee Takeda Bio Development Center Ltd with potential antineoplastic activity. This drug has been investigated in trials studying the treatment of sarcoma, lymphoma, oncology, colon cancer, and rectal cancer. Conatumumab can elicit the apoptosis in cell lines derived from colon and pancreatic cancers, as well as in mice bearing xenograft tumors in some in vitro and in vivo assays. Clinical trials in phase I has assessed the safety of conatumumab as a monotherapy as well as in combination with other antibody therapies or standard chemotherapeutic regimes. And the anti-conatumumab antibody responses have not been observed in previous trials. In addition, conatumumab has been found to enhance the antitumor activity of agents like irinotecan and gemcitabine in some preclinical researches. A trail about conatumumab combined with AMG 479 has shown that it is well-tolerated and no drug-drug interactions and the phase II development of this combination is ongoing.
Shipping
2-8 ℃
Note
For Research Use Only.
For research use only. Not for human or drug use.
